BioCentury
ARTICLE | Clinical News

TauRx's LMTX fails in Phase III AD study

July 27, 2016 7:00 AM UTC

TauRx Pharmaceuticals Ltd. (Singapore) said LMTX ( TRx0237) missed the co-primary endpoints in the Phase III TRx-237-015 trial as an add-on therapy to treat mild to moderate Alzheimer's disease. The candidate did not lead to significant improvements from baseline vs. control in ADCS-Activities of Daily Living (ADCS-ADL23) and 11-item Alzheimer's Disease Assessment Scale-Cognitive subscore (ADAS-Cog11) scores.

TauRx said there was also no significant difference between the groups on the level of brain atrophy as determined by lateral ventricular volume, the trial's principal secondary endpoint. The 891-patient trial studied 75 and 125 mg twice-daily oral LMTX for 15 months. ...